In the same vein, the PCa GnRH Agonists Simulator illustrated in the fourth use case can help to optimize the design of a clinical study by identifying the most promising drug formulations and dosing regimens, allowing to suppress testosterone levels below castration levels in most prostate cancer patients. The gene discussed is GNRH1; the disease is posterior cortical atrophy.